{"id":"comparators-simvastatin-and-ezetimibe","safety":{"commonSideEffects":[{"rate":null,"effect":"Myalgia / muscle pain"},{"rate":null,"effect":"Elevated liver transaminases"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Gastrointestinal upset"}]},"_chembl":{"chemblId":"CHEMBL1201391","moleculeType":"Small molecule","molecularWeight":"436.59"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Simvastatin reduces cholesterol synthesis in the liver by inhibiting HMG-CoA reductase, while ezetimibe selectively inhibits cholesterol absorption at the intestinal brush border via the Niemann-Pick C1-like 1 (NPC1L1) transporter. Together, they provide complementary lipid-lowering effects that are more potent than either agent alone.","oneSentence":"This is a combination therapy using simvastatin (a statin that inhibits HMG-CoA reductase) and ezetimibe (which blocks cholesterol absorption in the intestine) to lower LDL cholesterol through dual mechanisms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:21.259Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia / dyslipidemia for cardiovascular risk reduction"}]},"trialDetails":[{"nctId":"NCT00092651","phase":"PHASE3","title":"A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholesterolemia (0653A-038)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-09","conditions":"Hypercholesterolemia","enrollment":1398},{"nctId":"NCT01103648","phase":"NA","title":"Effect of Simvastatin and Ezetimibe on Lipid and Inflammation","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2005-06","conditions":"Prediabetes, Hypercholesterolemia, Inflammation","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":70,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Comparators: simvastatin and ezetimibe","genericName":"Comparators: simvastatin and ezetimibe","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Simvastatin and ezetimibe are two small molecule drugs used to treat conditions such as hypercholesterolemia, prediabetes, inflammation, and cardiovascular risk. They work through different mechanisms, with simvastatin primarily acting as a statin to lower cholesterol levels and ezetimibe inhibiting the absorption of cholesterol in the gut.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}